PEOPLE LIVING WITH ALS ELIGIBLE FOR COVID-19 VACCINATIONS STARTING FEBRUARY 25 UNDER ILLINOIS PHASE 1B; CHICAGO, COOK COUNTY EXCLUDED

lesturner Foundation Blog, Home Page

We are pleased to announce big changes in access to COVID-19 vaccinations for people living with ALS in Illinois. The State is making plans to expand COVID-19 Phase 1B vaccination eligibility on February 25 to people who have comorbidities and …

Foundation Advocating for COVID-19 Vaccination Prioritization for Individuals with ALS

lesturner Foundation Blog, Home Page

As we turn the calendar to 2021, the Les Turner ALS Foundation is taking proactive steps to help ensure that those living with neuromuscular disease, including ALS, are given priority access to COVID-19 vaccines and treatments. On Wednesday, January 6, Illinois …

Research May Lead to New Ways to Combat ALS

lesturner Foundation Blog, Home Page

Because we live in a changing environment, our survival and function depend on adapting to novel, potentially stressful, conditions. Is our ability to adapt to changing conditions fixed or is it possible to enhance our ability to tolerate a stressful …

Statement from Novartis Gene Therapies: OAV301 program for familial ALS caused by SOD1 mutation

lesturner Foundation Blog

Please see summary below from Novartis Gene Therapies on the OAV301 program for familial ALS caused by the SOD1 mutation: Novartis Gene Therapies (formerly AveXis) deeply appreciates the collaboration and support of the amyotrophic lateral sclerosis (ALS) community. Our ALS …

Amylyx Publishes CENTAUR Survival Data Demonstrating Statistically Significant Survival Benefit of AMX0035 for People with ALS

lesturner Foundation Blog, Home Page, Research & The Les Turner ALS Center

We are excited to share some promising data regarding the CENTAUR trial evaluating AMX0035 in people with ALS on overall survival analysis, published today (October 16, 2020)  in the neuromuscular disease journal Muscle & Nerve. The survival analysis followed each …